Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SALPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus SALPIX.
MPI INDIUM DTPA IN 111 vs SALPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
SALPIX (sodium chloride 0.9%, benzyl alcohol 0.9%) is a sterile, nonpyrogenic isotonic solution. It does not have a direct pharmacological mechanism of action; it is used as a vehicle or diluent for other medications and for irrigation. The benzyl alcohol component acts as a bacteriostatic preservative.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
SALPIX (hysterosalpingography contrast medium) is administered intrauterine as a single dose of 10-20 mL, instilled slowly under fluoroscopic guidance. No systemic dosing; procedure is diagnostic.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal elimination half-life: 1.5–2.0 hours. Short half-life necessitates frequent dosing in clinical use.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal excretion as unchanged drug: >90% within 24 hours. Minor biliary/fecal elimination (<10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical